PolyPid Ltd. (PYPD) Earnings Call Analysis

NASDAQ · Healthcare · Biotechnology

9/25

Growth 2 Margin 1 Expansion 3 Platform 1 Financial 2

latest quarter score

Earnings Reports

9
PolyPid (PYPD) Q2 2026: $320M Azurity Partnership Secures Commercial Launch Path Ahead of FDA PDUFA Date
August 12, 2026
7
PolyPID (PYPD) Q4 2025: R&D Spend Falls 11% as DPLEX 100 Nears Regulatory Milestone
June 15, 2026
9
PolyPID (PYPD) Q1 2026: NDA Submission Nears Completion as $4.3M PDUFA Waiver Bolsters Runway
May 13, 2026
8
Polypid (PYPD) Q3 2025: 58% SSI Reduction Drives DPLEX-100 Launch Momentum and Partner Interest
November 12, 2025
11
PolyPid (PYPD) Q2 2025: DPLEX-100 Cuts Surgical Infection Rates by 58%, Unlocking U.S. Partner Leverage
August 13, 2025
8
PolyPid (PYPD) Q1 2025: SHIELD II Enrollment Completes at 800 Patients, Paving Way for NDA Submission
May 14, 2025

Browse all companies